Antonio Llombart-Cussac, MD, PhD, Hospital Arnau de Vilanova, Valencia, Spain, reviews the results coming from the Phase II PARSIFAL-LONG trial, 5-year extended follow-up of the PARSIFAL study (NCT02491983). The trial assessed whether fulvestrant or letrozole was the optimal endocrine partner for the cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) palbociclib in patients with untreated, endocrine-sensitive, hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer in the first-line setting, failed to demonstrate an improvement in progression free survival. The Phase III EMERALD (NCT03778931) study reported data that identified early progressions on CDK4/6i as a strong predictor of resistance to subsequent endocrine therapies. The PARSIFAL-LONG is an extended follow-up analysis from the PARSIFAL study and confirmed no major differences between letrozole or fulvestrant when combined with palbociclib and noted that progression within the first year of first-line CDK4/6i-based regimens for HR+/HER2- advanced breast cancer patients may be prognostic of less favorable outcomes. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.